The Natural History and Reperfusion Therapy Outcomes of Acute Ischemic Stroke due to Isolated M2 Occlusions.


Journal

BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173

Informations de publication

Date de publication:
2021
Historique:
received: 27 12 2020
revised: 01 04 2021
accepted: 16 04 2021
entrez: 17 5 2021
pubmed: 18 5 2021
medline: 1 6 2021
Statut: epublish

Résumé

Currently, the standard treatment modality for patients with acute ischemic stroke (AIS) presenting with isolated M2 occlusions is not specific. We therefore assessed the difference in treatment outcomes for patients with isolated M2 occlusions. We retrospectively analyzed consecutive patients with AIS presenting with isolated M2 occlusions from October 1, 2018, to June 30, 2020. Patients were divided into 3 groups based on the treatments they received: no reperfusion therapy (NRT), intravenous thrombolysis treatment (IVT), and endovascular intervention (EVT), which comprised IVT in conjunction with EVT or EVT alone. The primary outcomes were improvements in modified Rankin Scale (mRS) scores at 90 days and National Institutes of Health Stroke Scale (NIHSS) scores at 24 hours after treatment compared with the baseline. The secondary efficacy outcome comprised a good outcome rate defined as a 90 - day mRS score ≤ 2, final infarct volume (FIV), 90-day mortality rate, and successful recanalization rate, which was defined as a modified thrombolysis in cerebral infarction score ≥ 2b. Safety outcomes included symptomatic intracerebral hemorrhage and procedure-related complications. Seventy patients were enrolled and divided into 3 groups: the NRT group ( For acute, isolated M2 occlusions, EVT could dramatically and rapidly improve neurological deficits with high safety and effectiveness. These changes were observed at 24 hours after treatment and were maintained over the long term.

Identifiants

pubmed: 33997031
doi: 10.1155/2021/6626604
pmc: PMC8096556
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6626604

Informations de copyright

Copyright © 2021 Hongmin Gong et al.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

JAMA Neurol. 2013 Jul;70(7):831-6
pubmed: 23699864
JAMA Neurol. 2016 Nov 1;73(11):1291-1296
pubmed: 27617425
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
AJNR Am J Neuroradiol. 2016 Apr;37(4):667-72
pubmed: 26564442
Exp Ther Med. 2020 Feb;19(2):891-896
pubmed: 32010249
J Neurol Sci. 2020 Aug 15;415:116873
pubmed: 32413798
J Neurointerv Surg. 2015 May;7(5):386-90
pubmed: 24714612
N Engl J Med. 2018 Apr 26;378(17):1573-1582
pubmed: 29694815
Eur Radiol. 2019 Feb;29(2):736-744
pubmed: 29987421
N Engl J Med. 2015 Mar 12;372(11):1009-18
pubmed: 25671797
JAMA. 2017 Aug 1;318(5):443-452
pubmed: 28763550
JAMA Neurol. 2014 Feb;71(2):151-7
pubmed: 24323077
Stroke. 2006 Apr;37(4):1000-4
pubmed: 16514102
Interv Neurol. 2020 Jan;8(2-6):180-186
pubmed: 32508900
Cerebrovasc Dis Extra. 2014 Mar 07;4(1):52-60
pubmed: 24715898
J Neuroimaging. 2014 Jul-Aug;24(4):354-8
pubmed: 24251821
J Neurointerv Surg. 2019 Nov;11(11):1065-1069
pubmed: 30975736
Stroke. 2010 Oct;41(10):2254-8
pubmed: 20829513
J Vasc Interv Neurol. 2017 Oct;9(5):8-14
pubmed: 29163743
JAMA. 2018 Sep 11;320(10):1017-1026
pubmed: 30208455
Lancet Neurol. 2016 Oct;15(11):1138-47
pubmed: 27567239
J Neurointerv Surg. 2015 Jul;7(7):478-83
pubmed: 24821842
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Front Neurol. 2017 Mar 14;8:98
pubmed: 28352248
Acad Radiol. 2012 Jun;19(6):701-7
pubmed: 22578227
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
AJNR Am J Neuroradiol. 2011 Oct;32(9):1640-5
pubmed: 21799045

Auteurs

Hongmin Gong (H)

Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
Chongqing Key Laboratory of Cerebrovascular Disease Research, Chongqing 402160, China.

Libo Zhao (L)

Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
Chongqing Key Laboratory of Cerebrovascular Disease Research, Chongqing 402160, China.

Ge Tang (G)

Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
Chongqing Key Laboratory of Cerebrovascular Disease Research, Chongqing 402160, China.

Yu Chen (Y)

Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
Chongqing Key Laboratory of Cerebrovascular Disease Research, Chongqing 402160, China.

Deyu Yang (D)

Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
Chongqing Key Laboratory of Cerebrovascular Disease Research, Chongqing 402160, China.

Shudong Liu (S)

Department of Neurology, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China.
Chongqing Key Laboratory of Cerebrovascular Disease Research, Chongqing 402160, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH